Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications
ASO Visual Abstract: Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response.
Journal: Annals of surgical oncology
Published: June 05, 2026
Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response.
Journal: Annals of surgical oncology
Published: December 03, 2025
Immune Checkpoint Inhibitor-Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position Statement.
Journal: JAMA oncology
Published: November 13, 2025
Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 02, 2025
Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
Journal: JAMA network open
Published: March 27, 2025
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Journal: Nature
Published: February 27, 2025
It Takes a Village! Navigating the Challenges and Opportunities in Immune-Related Adverse Event Management.
Journal: JCO oncology practice
Published: December 19, 2024
Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 03, 2024
Musculoskeletal ultrasound characteristics of checkpoint inhibitor-associated inflammatory arthritis.
Journal: Seminars in arthritis and rheumatism
Published: May 07, 2024
Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success.
Journal: Current oncology reports
Published: May 03, 2024
Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer.
Journal: JAMA network open
Published: April 22, 2024
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.
Journal: Journal for immunotherapy of cancer
Published: February 05, 2024
Last Updated: 09/26/2026